Janux Therapeutics and Bristol Myers Squibb (BMS) will develop a novel, tumor-activated therapeutic in an exclusive worldwide licensing agreement. Though as yet undisclosed, the therapeutic is targeting a validated solid tumor antigen expressed across several human cancer types.

As a clinical-stage biopharmaceutical company, Janux possesses a pipeline of novel immunotherapies developed via the company’s proprietary technologies. Among these are its Tumor Activated T Cell Engager, Tumor Activated Immunomodulator, and Adaptive Immune Response Modulator platforms.

Currently, Janux has two candidates in Phase I clinical trials.

Janux, BMS Agreement Terms

Breaking down the BMS agreement, Janux will complete preclinical development of the therapeutic up to Investigational New Drug (IND) submission. From there, BMS holds the IND and claim responsibility for subsequent development as well as global commercialization.

However, Janux will remain involved in the process, supporting BMS through completion of the first Phase I clinical study.

Tumor-Activated Therapeutics Market

“This collaboration marks a significant milestone for Janux, validating the strength of our tumor-activated platforms and expanding our reach in solid tumor oncology,” said David Campbell, PhD, President and CEO of Janux.

“By combining Janux’s innovative technology with [BMS]’s deep expertise in clinical development and global commercialization, we aim to accelerate the delivery of transformative therapies to patients with difficult-to-treat cancers,” Campbell added.

Money Breakdown of Janux–BMS Deal

On the monetary side of things, Janux may receive up to $50 million in combined upfront and near-term milestone payments. Additionally, the agreement entitles Janux to as much as $800 million for development, regulatory, and commercial milestones.

Lastly, Janux would be entitled to any tiered royalties from global product sales.